Frank Zhang is in the clear af­ter Chi­nese au­thor­i­ties con­clude in­ves­ti­ga­tion with­out charges, com­pa­ny says

The for­mer CEO of Gen­Script Biotech, a Hong Kong-list­ed CRO, is now ap­par­ent­ly cleared of any fur­ther in­ves­ti­ga­tions or pros­e­cu­tion in Chi­na.

Ac­cord­ing to the com­pa­ny, Fan­gliang “Frank” Zhang, along with three cur­rent em­ploy­ees and one for­mer em­ploy­ee of the com­pa­ny, have been no­ti­fied that Chi­nese au­thor­i­ties have de­cid­ed not to bring any charges against any en­ti­ty or in­di­vid­u­als. The de­ci­sion means that the pros­e­cu­tion, pro­ce­dure and any un­der­ly­ing in­ves­ti­ga­tion have now been con­clud­ed, the com­pa­ny said, and Gen­Script, its sub­sidiaries, Zhang and oth­er peo­ple re­lat­ed to the in­ves­ti­ga­tion will not have any crim­i­nal li­a­bil­i­ty at­tached to the in­ves­ti­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER